CURIS INC
CRISDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Jun 30, 2026
9dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
Trial Start - TakeAim CLL
For Chronic Lymphocytic Leukemia. Curis anticipates initial 5-patient dosing in the TakeAim CLL trial by mid-2026 and projects sufficient cash runway extending into the second half of 2027.
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Ibrutinib
Relapsed Hematologic Malignancy
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Ibrutinib | Phase 2 | Relapsed Hematologic Malignancy | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |